The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States

Nonalcoholic fatty liver disease (NAFLD) is a global public health problem. However, the natural history of NAFLD is incomplete. This is a retrospective cohort study of patients identified with NAFLD by diagnosis codes in a large, community‐based health care delivery system. The objectives were (1)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hepatology communications 2021-01, Vol.5 (1), p.83-96
Hauptverfasser: Nyberg, Lisa M., Cheetham, T. Craig, Patton, Heather M., Yang, Su‐Jau, Chiang, Kevin M., Caparosa, Susan L., Stern, Julie A., Nyberg, Anders H.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 96
container_issue 1
container_start_page 83
container_title Hepatology communications
container_volume 5
creator Nyberg, Lisa M.
Cheetham, T. Craig
Patton, Heather M.
Yang, Su‐Jau
Chiang, Kevin M.
Caparosa, Susan L.
Stern, Julie A.
Nyberg, Anders H.
description Nonalcoholic fatty liver disease (NAFLD) is a global public health problem. However, the natural history of NAFLD is incomplete. This is a retrospective cohort study of patients identified with NAFLD by diagnosis codes in a large, community‐based health care delivery system. The objectives were (1) to follow patients from initial NAFLD presentation through progression to cirrhosis and/or decompensated cirrhosis to liver cancer, liver transplant, and death for up to 10 years; and (2) to conduct disease progression analysis restricted to patients with NAFLD identified as having diabetes at baseline. A total of 98,164 patients with full NAFLD and 26,488 with diabetes were divided into three baseline prevalent states: (1) no cirrhosis, (2) compensated cirrhosis, and (3) decompensated cirrhosis. In baseline patients without cirrhosis, annual rates of compensated cirrhosis, decompensated cirrhosis, and death were 0.28%, 0.31%, and 0.63% per year, respectively. With baseline compensated cirrhosis, the annual rates of decompensation and death were 2.4% and 6.7% per year. Finally, in those with decompensated cirrhosis at baseline, the death rate was 8.0% per year. In those without cirrhosis and with cirrhosis at baseline, the rates of liver cancer and death were increased approximately 2‐fold in the diabetic subpopulation compared with the full NAFLD cohort. Age and comorbidities increased with increasing disease severity. Cox proportional hazards regression analysis showed that cirrhosis was strongly associated with death and liver cancer, and that diabetes was associated with a significant increase in the hazard of both liver cancer and death (2.56 [2.04‐3.20] and 1.43 [1.35‐1.52]), respectively. Conclusion: The findings of this community‐based study further our understanding of the natural history of NAFLD and demonstrate that diabetes is a major factor in the progression of this disease.
doi_str_mv 10.1002/hep4.1625
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7789841</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2475794325</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4715-a80747746feb7425a0615675b6084722c0f03c5ecba77d67f10b7c90d1d00e243</originalsourceid><addsrcrecordid>eNp1kdFKHDEUhkNpqWK96AuUQG8quHqSSSY7NwW7aldYbEGF3oXMzBk3MjPZJhll7nyEPmOfpFlXxRZ6lcD58uWc8xPynsEBA-CHS1yJA5Zz-Ypsc6HYhEvx4_WL-xbZDeEGAFjBGSvgLdnKMpGpArJtEi6XSM9NHLxp6dyG6PxIXUPPj04Xx_vU0JnruqG3cfx9_-uLCVjTizjUIzUxFRfGXyOdo2njks6MR3qMrb3F5LgYQ8SO2p7G9MNVMjw8NRHDO_KmMW3A3cdzh1ydnlzO5pPFt69ns6PFpEqty4mZghJKibzBUgkuDeRM5kqWOUyF4ryCBrJKYlUapepcNQxKVRVQsxoAuch2yOeNdzWUHdYV9jFNqVfedsaP2hmr_670dqmv3a1WalpMBUuCT48C734OGKLubKiwbU2Pbgg6rVhJKLjME_rxH_TGDb5P460pqQqRcZmovQ1VeReCx-a5GQZ6naZep6nXaSb2w8vun8mn7BJwuAHubIvj_016fvJdPCj_AEAVqGo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2475794325</pqid></control><display><type>article</type><title>The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Access via Wiley Online Library</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Nyberg, Lisa M. ; Cheetham, T. Craig ; Patton, Heather M. ; Yang, Su‐Jau ; Chiang, Kevin M. ; Caparosa, Susan L. ; Stern, Julie A. ; Nyberg, Anders H.</creator><creatorcontrib>Nyberg, Lisa M. ; Cheetham, T. Craig ; Patton, Heather M. ; Yang, Su‐Jau ; Chiang, Kevin M. ; Caparosa, Susan L. ; Stern, Julie A. ; Nyberg, Anders H.</creatorcontrib><description>Nonalcoholic fatty liver disease (NAFLD) is a global public health problem. However, the natural history of NAFLD is incomplete. This is a retrospective cohort study of patients identified with NAFLD by diagnosis codes in a large, community‐based health care delivery system. The objectives were (1) to follow patients from initial NAFLD presentation through progression to cirrhosis and/or decompensated cirrhosis to liver cancer, liver transplant, and death for up to 10 years; and (2) to conduct disease progression analysis restricted to patients with NAFLD identified as having diabetes at baseline. A total of 98,164 patients with full NAFLD and 26,488 with diabetes were divided into three baseline prevalent states: (1) no cirrhosis, (2) compensated cirrhosis, and (3) decompensated cirrhosis. In baseline patients without cirrhosis, annual rates of compensated cirrhosis, decompensated cirrhosis, and death were 0.28%, 0.31%, and 0.63% per year, respectively. With baseline compensated cirrhosis, the annual rates of decompensation and death were 2.4% and 6.7% per year. Finally, in those with decompensated cirrhosis at baseline, the death rate was 8.0% per year. In those without cirrhosis and with cirrhosis at baseline, the rates of liver cancer and death were increased approximately 2‐fold in the diabetic subpopulation compared with the full NAFLD cohort. Age and comorbidities increased with increasing disease severity. Cox proportional hazards regression analysis showed that cirrhosis was strongly associated with death and liver cancer, and that diabetes was associated with a significant increase in the hazard of both liver cancer and death (2.56 [2.04‐3.20] and 1.43 [1.35‐1.52]), respectively. Conclusion: The findings of this community‐based study further our understanding of the natural history of NAFLD and demonstrate that diabetes is a major factor in the progression of this disease.</description><identifier>ISSN: 2471-254X</identifier><identifier>EISSN: 2471-254X</identifier><identifier>DOI: 10.1002/hep4.1625</identifier><identifier>PMID: 33437903</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health Medical Research, Lippincott Williams &amp; Wilkins</publisher><subject>Adult ; Aged ; Algorithms ; Ascites ; Body mass index ; Clinical outcomes ; Codes ; Comorbidity ; Diabetes ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - mortality ; Disease Progression ; Endoscopy ; Female ; Health care delivery ; Hepatitis ; Humans ; Liver cancer ; Liver cirrhosis ; Liver Cirrhosis - epidemiology ; Liver Cirrhosis - mortality ; Liver diseases ; Liver Neoplasms - epidemiology ; Liver Neoplasms - mortality ; Liver Transplantation - statistics &amp; numerical data ; Liver transplants ; Male ; Medical records ; Middle Aged ; Mortality ; Non-alcoholic Fatty Liver Disease - complications ; Non-alcoholic Fatty Liver Disease - epidemiology ; Non-alcoholic Fatty Liver Disease - mortality ; Original ; Population ; Primary care ; Public health ; Regression Analysis ; Retrospective Studies ; Severity of Illness Index ; United States - epidemiology</subject><ispartof>Hepatology communications, 2021-01, Vol.5 (1), p.83-96</ispartof><rights>2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of the American Association for the Study of Liver Diseases.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4715-a80747746feb7425a0615675b6084722c0f03c5ecba77d67f10b7c90d1d00e243</citedby><orcidid>0000-0003-3581-5237 ; 0000-0001-5869-9924 ; 0000-0001-6209-8929 ; 0000-0001-9625-7705 ; 0000-0002-0625-3653 ; 0000-0002-0888-0810 ; 0000-0001-7363-4969 ; 0000-0002-0972-0720</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789841/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789841/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33437903$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nyberg, Lisa M.</creatorcontrib><creatorcontrib>Cheetham, T. Craig</creatorcontrib><creatorcontrib>Patton, Heather M.</creatorcontrib><creatorcontrib>Yang, Su‐Jau</creatorcontrib><creatorcontrib>Chiang, Kevin M.</creatorcontrib><creatorcontrib>Caparosa, Susan L.</creatorcontrib><creatorcontrib>Stern, Julie A.</creatorcontrib><creatorcontrib>Nyberg, Anders H.</creatorcontrib><title>The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States</title><title>Hepatology communications</title><addtitle>Hepatol Commun</addtitle><description>Nonalcoholic fatty liver disease (NAFLD) is a global public health problem. However, the natural history of NAFLD is incomplete. This is a retrospective cohort study of patients identified with NAFLD by diagnosis codes in a large, community‐based health care delivery system. The objectives were (1) to follow patients from initial NAFLD presentation through progression to cirrhosis and/or decompensated cirrhosis to liver cancer, liver transplant, and death for up to 10 years; and (2) to conduct disease progression analysis restricted to patients with NAFLD identified as having diabetes at baseline. A total of 98,164 patients with full NAFLD and 26,488 with diabetes were divided into three baseline prevalent states: (1) no cirrhosis, (2) compensated cirrhosis, and (3) decompensated cirrhosis. In baseline patients without cirrhosis, annual rates of compensated cirrhosis, decompensated cirrhosis, and death were 0.28%, 0.31%, and 0.63% per year, respectively. With baseline compensated cirrhosis, the annual rates of decompensation and death were 2.4% and 6.7% per year. Finally, in those with decompensated cirrhosis at baseline, the death rate was 8.0% per year. In those without cirrhosis and with cirrhosis at baseline, the rates of liver cancer and death were increased approximately 2‐fold in the diabetic subpopulation compared with the full NAFLD cohort. Age and comorbidities increased with increasing disease severity. Cox proportional hazards regression analysis showed that cirrhosis was strongly associated with death and liver cancer, and that diabetes was associated with a significant increase in the hazard of both liver cancer and death (2.56 [2.04‐3.20] and 1.43 [1.35‐1.52]), respectively. Conclusion: The findings of this community‐based study further our understanding of the natural history of NAFLD and demonstrate that diabetes is a major factor in the progression of this disease.</description><subject>Adult</subject><subject>Aged</subject><subject>Algorithms</subject><subject>Ascites</subject><subject>Body mass index</subject><subject>Clinical outcomes</subject><subject>Codes</subject><subject>Comorbidity</subject><subject>Diabetes</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - mortality</subject><subject>Disease Progression</subject><subject>Endoscopy</subject><subject>Female</subject><subject>Health care delivery</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Liver Cirrhosis - epidemiology</subject><subject>Liver Cirrhosis - mortality</subject><subject>Liver diseases</subject><subject>Liver Neoplasms - epidemiology</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Transplantation - statistics &amp; numerical data</subject><subject>Liver transplants</subject><subject>Male</subject><subject>Medical records</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Non-alcoholic Fatty Liver Disease - complications</subject><subject>Non-alcoholic Fatty Liver Disease - epidemiology</subject><subject>Non-alcoholic Fatty Liver Disease - mortality</subject><subject>Original</subject><subject>Population</subject><subject>Primary care</subject><subject>Public health</subject><subject>Regression Analysis</subject><subject>Retrospective Studies</subject><subject>Severity of Illness Index</subject><subject>United States - epidemiology</subject><issn>2471-254X</issn><issn>2471-254X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kdFKHDEUhkNpqWK96AuUQG8quHqSSSY7NwW7aldYbEGF3oXMzBk3MjPZJhll7nyEPmOfpFlXxRZ6lcD58uWc8xPynsEBA-CHS1yJA5Zz-Ypsc6HYhEvx4_WL-xbZDeEGAFjBGSvgLdnKMpGpArJtEi6XSM9NHLxp6dyG6PxIXUPPj04Xx_vU0JnruqG3cfx9_-uLCVjTizjUIzUxFRfGXyOdo2njks6MR3qMrb3F5LgYQ8SO2p7G9MNVMjw8NRHDO_KmMW3A3cdzh1ydnlzO5pPFt69ns6PFpEqty4mZghJKibzBUgkuDeRM5kqWOUyF4ryCBrJKYlUapepcNQxKVRVQsxoAuch2yOeNdzWUHdYV9jFNqVfedsaP2hmr_670dqmv3a1WalpMBUuCT48C734OGKLubKiwbU2Pbgg6rVhJKLjME_rxH_TGDb5P460pqQqRcZmovQ1VeReCx-a5GQZ6naZep6nXaSb2w8vun8mn7BJwuAHubIvj_016fvJdPCj_AEAVqGo</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Nyberg, Lisa M.</creator><creator>Cheetham, T. Craig</creator><creator>Patton, Heather M.</creator><creator>Yang, Su‐Jau</creator><creator>Chiang, Kevin M.</creator><creator>Caparosa, Susan L.</creator><creator>Stern, Julie A.</creator><creator>Nyberg, Anders H.</creator><general>Wolters Kluwer Health Medical Research, Lippincott Williams &amp; Wilkins</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3581-5237</orcidid><orcidid>https://orcid.org/0000-0001-5869-9924</orcidid><orcidid>https://orcid.org/0000-0001-6209-8929</orcidid><orcidid>https://orcid.org/0000-0001-9625-7705</orcidid><orcidid>https://orcid.org/0000-0002-0625-3653</orcidid><orcidid>https://orcid.org/0000-0002-0888-0810</orcidid><orcidid>https://orcid.org/0000-0001-7363-4969</orcidid><orcidid>https://orcid.org/0000-0002-0972-0720</orcidid></search><sort><creationdate>202101</creationdate><title>The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States</title><author>Nyberg, Lisa M. ; Cheetham, T. Craig ; Patton, Heather M. ; Yang, Su‐Jau ; Chiang, Kevin M. ; Caparosa, Susan L. ; Stern, Julie A. ; Nyberg, Anders H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4715-a80747746feb7425a0615675b6084722c0f03c5ecba77d67f10b7c90d1d00e243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Algorithms</topic><topic>Ascites</topic><topic>Body mass index</topic><topic>Clinical outcomes</topic><topic>Codes</topic><topic>Comorbidity</topic><topic>Diabetes</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - mortality</topic><topic>Disease Progression</topic><topic>Endoscopy</topic><topic>Female</topic><topic>Health care delivery</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Liver Cirrhosis - epidemiology</topic><topic>Liver Cirrhosis - mortality</topic><topic>Liver diseases</topic><topic>Liver Neoplasms - epidemiology</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Transplantation - statistics &amp; numerical data</topic><topic>Liver transplants</topic><topic>Male</topic><topic>Medical records</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Non-alcoholic Fatty Liver Disease - complications</topic><topic>Non-alcoholic Fatty Liver Disease - epidemiology</topic><topic>Non-alcoholic Fatty Liver Disease - mortality</topic><topic>Original</topic><topic>Population</topic><topic>Primary care</topic><topic>Public health</topic><topic>Regression Analysis</topic><topic>Retrospective Studies</topic><topic>Severity of Illness Index</topic><topic>United States - epidemiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nyberg, Lisa M.</creatorcontrib><creatorcontrib>Cheetham, T. Craig</creatorcontrib><creatorcontrib>Patton, Heather M.</creatorcontrib><creatorcontrib>Yang, Su‐Jau</creatorcontrib><creatorcontrib>Chiang, Kevin M.</creatorcontrib><creatorcontrib>Caparosa, Susan L.</creatorcontrib><creatorcontrib>Stern, Julie A.</creatorcontrib><creatorcontrib>Nyberg, Anders H.</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatology communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nyberg, Lisa M.</au><au>Cheetham, T. Craig</au><au>Patton, Heather M.</au><au>Yang, Su‐Jau</au><au>Chiang, Kevin M.</au><au>Caparosa, Susan L.</au><au>Stern, Julie A.</au><au>Nyberg, Anders H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States</atitle><jtitle>Hepatology communications</jtitle><addtitle>Hepatol Commun</addtitle><date>2021-01</date><risdate>2021</risdate><volume>5</volume><issue>1</issue><spage>83</spage><epage>96</epage><pages>83-96</pages><issn>2471-254X</issn><eissn>2471-254X</eissn><abstract>Nonalcoholic fatty liver disease (NAFLD) is a global public health problem. However, the natural history of NAFLD is incomplete. This is a retrospective cohort study of patients identified with NAFLD by diagnosis codes in a large, community‐based health care delivery system. The objectives were (1) to follow patients from initial NAFLD presentation through progression to cirrhosis and/or decompensated cirrhosis to liver cancer, liver transplant, and death for up to 10 years; and (2) to conduct disease progression analysis restricted to patients with NAFLD identified as having diabetes at baseline. A total of 98,164 patients with full NAFLD and 26,488 with diabetes were divided into three baseline prevalent states: (1) no cirrhosis, (2) compensated cirrhosis, and (3) decompensated cirrhosis. In baseline patients without cirrhosis, annual rates of compensated cirrhosis, decompensated cirrhosis, and death were 0.28%, 0.31%, and 0.63% per year, respectively. With baseline compensated cirrhosis, the annual rates of decompensation and death were 2.4% and 6.7% per year. Finally, in those with decompensated cirrhosis at baseline, the death rate was 8.0% per year. In those without cirrhosis and with cirrhosis at baseline, the rates of liver cancer and death were increased approximately 2‐fold in the diabetic subpopulation compared with the full NAFLD cohort. Age and comorbidities increased with increasing disease severity. Cox proportional hazards regression analysis showed that cirrhosis was strongly associated with death and liver cancer, and that diabetes was associated with a significant increase in the hazard of both liver cancer and death (2.56 [2.04‐3.20] and 1.43 [1.35‐1.52]), respectively. Conclusion: The findings of this community‐based study further our understanding of the natural history of NAFLD and demonstrate that diabetes is a major factor in the progression of this disease.</abstract><cop>United States</cop><pub>Wolters Kluwer Health Medical Research, Lippincott Williams &amp; Wilkins</pub><pmid>33437903</pmid><doi>10.1002/hep4.1625</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0003-3581-5237</orcidid><orcidid>https://orcid.org/0000-0001-5869-9924</orcidid><orcidid>https://orcid.org/0000-0001-6209-8929</orcidid><orcidid>https://orcid.org/0000-0001-9625-7705</orcidid><orcidid>https://orcid.org/0000-0002-0625-3653</orcidid><orcidid>https://orcid.org/0000-0002-0888-0810</orcidid><orcidid>https://orcid.org/0000-0001-7363-4969</orcidid><orcidid>https://orcid.org/0000-0002-0972-0720</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2471-254X
ispartof Hepatology communications, 2021-01, Vol.5 (1), p.83-96
issn 2471-254X
2471-254X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7789841
source MEDLINE; DOAJ Directory of Open Access Journals; Access via Wiley Online Library; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central
subjects Adult
Aged
Algorithms
Ascites
Body mass index
Clinical outcomes
Codes
Comorbidity
Diabetes
Diabetes Mellitus - epidemiology
Diabetes Mellitus - mortality
Disease Progression
Endoscopy
Female
Health care delivery
Hepatitis
Humans
Liver cancer
Liver cirrhosis
Liver Cirrhosis - epidemiology
Liver Cirrhosis - mortality
Liver diseases
Liver Neoplasms - epidemiology
Liver Neoplasms - mortality
Liver Transplantation - statistics & numerical data
Liver transplants
Male
Medical records
Middle Aged
Mortality
Non-alcoholic Fatty Liver Disease - complications
Non-alcoholic Fatty Liver Disease - epidemiology
Non-alcoholic Fatty Liver Disease - mortality
Original
Population
Primary care
Public health
Regression Analysis
Retrospective Studies
Severity of Illness Index
United States - epidemiology
title The Natural History of NAFLD, a Community‐Based Study at a Large Health Care Delivery System in the United States
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A55%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Natural%20History%20of%20NAFLD,%20a%20Community%E2%80%90Based%20Study%20at%20a%20Large%20Health%20Care%20Delivery%20System%20in%20the%20United%20States&rft.jtitle=Hepatology%20communications&rft.au=Nyberg,%20Lisa%20M.&rft.date=2021-01&rft.volume=5&rft.issue=1&rft.spage=83&rft.epage=96&rft.pages=83-96&rft.issn=2471-254X&rft.eissn=2471-254X&rft_id=info:doi/10.1002/hep4.1625&rft_dat=%3Cproquest_pubme%3E2475794325%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2475794325&rft_id=info:pmid/33437903&rfr_iscdi=true